Brief: FDA Files Corcept’s New Drug Application For Relacorilant As Treatment For Patients With Hypercortisolism
03/03/2025 21:07
March 3 (Reuters) - Corcept Therapeutics Inc CORT.O: FDA FILES CORCEPT’S NEW DRUG APPLICATION FOR RELACORILANT AS TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM Source text: ID:nBw5jD1c5a Further company coverage: CORT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corcept Therapeutics Incorporated
See all newsDrugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case
Live Markets: US earnings forecast jumps further after key reports this week
Live Markets: Who's next for the S&P 500? The clock is ticking
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary